Soberana Plus
A vial of Soberana Plus | |
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Conjugate |
Clinical data | |
Trade names | Pasteur |
Other names | FINLAY-FR-1A |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
Part of a series on the |
COVID-19 pandemic |
---|
|
Medical response |
|
|
Soberana Plus, technical name FINLAY-FR-1A, is a COVID-19 candidate vaccine produced by the Finlay Institute, a Cuban epidemiological research institute.[1]
Medical uses
[edit]It can be used as a third (booster) dose for Soberana 02 vaccine at eight weeks.[2][3][4] It's also studied as an independent single-dose vaccine.[1][5][6]
Efficacy
[edit]It combined the Soberana 02, the vaccine booster shot shows an efficacy of 91.2%.[7] The final result of a third dose of Soberana Plus increased the efficacy up to 92.4%.[8] Efficacy against severe disease and death is 100% for the heterologous three-dose regimen.[9]
Clinical trials
[edit]Booster dose
[edit]Soberana Plus has also been studied as a booster dose for Soberana 02.[10][11]
Single dose
[edit]Phase | Registration | Number of participants | Age of participants | |||
---|---|---|---|---|---|---|
ID | Date | Total | Vaccine | Control | ||
I | RPCEC00000349 | 2021-01-05 | 30 | 30 | 0 | 18-55 years |
IIa | RPCEC00000366 | 2021-04-09 | 20 | 20 | 0 | 19-80 years |
IIb | 430 | Placebo-controlled |
Authorizations
[edit]On 20 August 2021, Cuba approved Soberana Plus as a booster after two doses of Soberana 02.[12] On 23 September, Cuba approved Soberana Plus for COVID-19 survivors over 19 years old. On 7 December, the authorization was expanded to include COVID-19 survivors from 2 to 18 years old.[13]
See also
[edit]References
[edit]- ^ a b Cuban Registry of Clinical Trials. "SOBERANA PLUS". Retrieved 2021-09-08.
- ^ "ماجرای تزریق اشتباهی واکسن کرونا" [The story of the wrong injection of the corona vaccine]. Iranian Students' News Agency (ISNA) (in Persian). 2021-08-31. Retrieved 2021-09-08.
- ^ Cuban Registry of Clinical Trials. "SOBERANA 02-FaseIII". Retrieved 2021-09-08.
- ^ "IRCT | Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years". www.irct.ir. Retrieved 2021-09-08.
- ^ Cuban Registry of Clinical Trials. "SOBERANA 01B". Retrieved 2021-09-08.
- ^ Chang-Monteagudo A, Ochoa-Azze R, Climent-Ruiz Y, Macias-Abraham C, Rodriguez-Noda L, Valenzuela-Silva C, et al. (2021). "A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial". medRxiv 10.1101/2021.02.22.21252091.
- ^ "Cuba says second COVID-19 vaccine Soberana 2 boasts 91.2% efficacy". Reuters. Retrieved 2021-09-23.
- ^ Toledo-Romani ME, Garcia-Carmenate M, Silva CV, Baldoquin-Rodriguez W, Pérez MM, Gonzalez MC, Moreno BP, Hernández IC, et al. (2021-11-01). "Efficacy and Safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three doses combination": 2021.10.31.21265703. doi:10.1101/2021.10.31.21265703. S2CID 240302516.
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ Toledo-Romani ME, Garcia-Carmenate M, Silva CV, Baldoquin-Rodriguez W, Perez MM, Gonzalez MC, et al. (2021-11-06). "Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination": 2021.10.31.21265703. doi:10.1101/2021.10.31.21265703. S2CID 240302516.
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ "SOBERANA 02-FaseIII". Retrieved 2021-09-09.
- ^ "IRCT | Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years". en.irct.ir. Archived from the original on 2021-09-07. Retrieved 2021-09-07.
- ^ Dönmez BB (21 August 2021). "Cuba grants emergency use to 2 virus vaccines". Anadolu Agency. Retrieved 23 September 2021.
- ^ "Commercial file SOBERANA Plus Eng" (PDF). finlay.edu.cu.
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
- CS1 Persian-language sources (fa)
- CS1 errors: missing periodical
- Articles with short description
- Short description matches Wikidata
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine